• 1. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 2. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 3. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 4. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 5. Distinct impact of glycation towards the aggregation and toxicity of murine and human amyloid-β?
  Eunju Nam,Jiyeon Han,Sunhee Choi,Mi Hee Lim Chem. Commun., 2021,57, 7637-7640

Professional Introduction to Zeaxanthin Myristate Palmitate (CAS No. 115095-08-4)

Zeaxanthin Myristate Palmitate, a compound with the chemical identifier CAS No. 115095-08-4, represents a significant advancement in the field of nutritional science and pharmacology. This compound is a derivative of zeaxanthin, a carotenoid known for its potent antioxidant properties and role in maintaining eye health. The myristate and palmitate esters enhance the solubility and bioavailability of zeaxanthin, making it an attractive candidate for various therapeutic applications.

The structural modification of zeaxanthin into its myristate and palmitate forms has been extensively studied for its potential benefits in combating oxidative stress and inflammation. Recent research has highlighted the compound's efficacy in protecting retinal cells from damage caused by free radicals, thereby reducing the risk of age-related macular degeneration (AMD). This protective effect is attributed to the compound's ability to penetrate the blood-brain barrier, offering neuroprotective benefits beyond ocular health.

One of the most compelling aspects of Zeaxanthin Myristate Palmitate is its enhanced absorption rate compared to free zeaxanthin. Studies have demonstrated that this esterified form of zeaxanthin exhibits superior bioavailability, allowing for more efficient delivery to target tissues. This improvement in absorption is particularly relevant in formulations designed for patients with impaired lipid metabolism, where traditional carotenoid supplements may be less effective.

Furthermore, Zeaxanthin Myristate Palmitate has shown promise in clinical trials for its anti-inflammatory properties. Chronic inflammation is a hallmark of numerous pathological conditions, including cardiovascular disease, diabetes, and autoimmune disorders. The compound's ability to modulate inflammatory pathways suggests its potential as a therapeutic agent in managing these conditions. Initial findings indicate that it can reduce levels of pro-inflammatory cytokines, such as TNF-α and IL-6, without causing significant side effects.

The pharmacokinetic profile of Zeaxanthin Myristate Palmitate has been another area of intense investigation. Unlike free zeaxanthin, which has a relatively short half-life in the bloodstream, this esterified form exhibits prolonged circulation time. This extended presence allows for more sustained therapeutic effects and reduces the frequency of dosing required. Such pharmacokinetic advantages make it an ideal candidate for long-term therapeutic regimens.

Recent advancements in nanotechnology have also opened new avenues for the application of Zeaxanthin Myristate Palmitate. Researchers have developed nanoencapsulated formulations that enhance the stability and targeted delivery of this compound. These nanoformulations have shown increased penetration into cellular compartments, particularly beneficial for treatments requiring intracellular action. The potential to customize nanoparticle size and surface properties further expands the therapeutic applications of this compound.

The role of Zeaxanthin Myristate Palmitate in skin health has also garnered attention. Its antioxidant properties help mitigate damage caused by UV radiation and environmental pollutants, making it a valuable component in cosmetic formulations aimed at preventing photodamage and premature aging. Additionally, its anti-inflammatory effects contribute to reducing skin redness and irritation associated with various dermatological conditions.

From a regulatory perspective, Zeaxanthin Myristate Palmitate has undergone rigorous safety assessments to ensure its suitability for human consumption and therapeutic use. Regulatory bodies such as the FDA and EMA have recognized its potential benefits while emphasizing the need for further clinical studies to establish optimal dosing regimens and long-term safety profiles. These regulatory approvals provide confidence to healthcare professionals and consumers regarding its use.

In conclusion, Zeaxanthin Myristate Palmitate (CAS No. 115095-08-4) represents a significant advancement in nutritional science and pharmacology. Its enhanced bioavailability, prolonged circulation time, and multifaceted therapeutic effects make it a versatile compound with applications ranging from eye health to anti-inflammatory treatments. As research continues to uncover new insights into its mechanisms of action, it is poised to play an increasingly important role in preventive medicine and chronic disease management.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)